Research record
CML controlled with regular TKI medicine
If leukemia is stable on regular medicine with a good survival outlook, one common pattern to clarify is chronic-phase CML controlled by a BCR-ABL tyrosine kinase inhibitor.
What this is
If leukemia is stable on regular medicine with a good survival outlook, one common pattern to clarify is chronic-phase CML controlled by a BCR-ABL tyrosine kinase inhibitor.
Why it may come up
- stable chronic phase CML
- long-term medicine
- molecular monitoring
What not to assume
- Do not recommend stopping TKI medicine.
- Do not assume stable disease means cured.
- Do not compare transplant and medicine without subtype, phase, response depth, donor, and center-specific risk.
At a glance
CML controlled with regular TKI medicine
- Type
- Targeted therapy
- Mutation result
- BCR-ABL / Philadelphia chromosome context
- Where
- Global
- Evidence status
- Source gives context
- Last checked
- 2026-05-21
What we know
- NCI CML sources describe targeted therapy with tyrosine kinase inhibitors as central CML treatment context.
- CML follow-up often uses molecular response language, so families may hear BCR-ABL, PCR, MMR, deep molecular response, or treatment-free remission.
What is unclear
- The friend's exact leukemia subtype is not known from the description.
- Stable medicine-controlled leukemia could still involve different risk groups, response depths, side effects, or future goals.
Questions to ask
- Does the report say CML, BCR-ABL, or Philadelphia chromosome positive?
- What response level is documented: complete hematologic, cytogenetic, major molecular, or deep molecular response?
- Is the current goal ongoing control, treatment-free remission attempt, transplant evaluation, or another goal?
Timeline
- publication2018: NCI discusses selected CML TKI discontinuation context
Supports careful-monitoring language around treatment-free remission attempts, not self-stopping medicine.
Related trial leads
NCI
Tyrosine kinase inhibitor cessation for chronic myeloid leukemia patients with stable molecular response
Supports the treatment-free remission research context for selected CML patients with stable molecular response.